Schroder Investment Management Group Acquires 178,546 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Schroder Investment Management Group lifted its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 76.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 413,550 shares of the biotechnology company's stock after purchasing an additional 178,546 shares during the quarter. Schroder Investment Management Group owned 0.45% of Rocket Pharmaceuticals worth $4,975,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Signaturefd LLC boosted its position in shares of Rocket Pharmaceuticals by 319.8% during the fourth quarter. Signaturefd LLC now owns 4,916 shares of the biotechnology company's stock worth $62,000 after purchasing an additional 3,745 shares in the last quarter. Harbour Investments Inc. boosted its position in shares of Rocket Pharmaceuticals by 51.9% during the fourth quarter. Harbour Investments Inc. now owns 5,385 shares of the biotechnology company's stock worth $68,000 after purchasing an additional 1,840 shares in the last quarter. KBC Group NV boosted its position in shares of Rocket Pharmaceuticals by 159.6% during the fourth quarter. KBC Group NV now owns 5,475 shares of the biotechnology company's stock worth $69,000 after purchasing an additional 3,366 shares in the last quarter. E Fund Management Co. Ltd. bought a new position in shares of Rocket Pharmaceuticals during the fourth quarter worth $139,000. Finally, Strategic Financial Concepts LLC bought a new position in shares of Rocket Pharmaceuticals during the fourth quarter worth $141,000. 98.39% of the stock is owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts recently commented on RCKT shares. The Goldman Sachs Group cut their price objective on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Jefferies Financial Group started coverage on shares of Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They issued a "buy" rating and a $29.00 price target on the stock. Chardan Capital lowered their price objective on shares of Rocket Pharmaceuticals from $62.00 to $54.00 and set a "buy" rating on the stock in a research note on Friday, February 28th. BMO Capital Markets started coverage on shares of Rocket Pharmaceuticals in a research note on Wednesday, March 12th. They set an "outperform" rating and a $50.00 price objective on the stock. Finally, Canaccord Genuity Group lowered their price objective on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.00.

Rocket Pharmaceuticals Price Performance

Shares of Rocket Pharmaceuticals stock traded down $0.31 on Thursday, reaching $5.09. 815,720 shares of the stock were exchanged, compared to its average volume of 1,196,376. The firm's 50 day moving average is $8.61 and its 200-day moving average is $12.27. Rocket Pharmaceuticals, Inc. has a one year low of $4.55 and a one year high of $26.98. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05. The firm has a market cap of $542.75 million, a PE ratio of -1.85 and a beta of 1.00.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.06. As a group, analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.

Insider Activity at Rocket Pharmaceuticals

In related news, CFO Aaron Ondrey sold 7,489 shares of the stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $5.29, for a total value of $39,616.81. Following the completion of the transaction, the chief financial officer now owns 129,650 shares of the company's stock, valued at $685,848.50. This represents a 5.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 28.50% of the stock is owned by insiders.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.